PRESS RELEASE published on 05/17/2023 at 12:30, 3 years 4 months ago Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis
PRESS RELEASE published on 05/06/2023 at 12:30, 3 years 5 months ago Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action
PRESS RELEASE published on 05/04/2023 at 12:30, 3 years 5 months ago Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders
PRESS RELEASE published on 04/27/2023 at 12:30, 3 years 5 months ago Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.
PRESS RELEASE published on 04/26/2023 at 12:30, 3 years 5 months ago Immunic to Participate in Investor and Scientific Conferences in May
PRESS RELEASE published on 04/05/2023 at 12:30, 3 years 6 months ago Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis
PRESS RELEASE published on 03/02/2023 at 12:30, 3 years 7 months ago Immunic to Participate in Investor and Scientific Conferences in March
PRESS RELEASE published on 02/22/2023 at 12:30, 3 years 7 months ago Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023
PRESS RELEASE published on 02/09/2023 at 12:30, 3 years 7 months ago Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need
PRESS RELEASE published on 01/25/2023 at 12:30, 3 years 8 months ago Immunic to Participate in Scientific and Investor Conferences in February
Published on 10/07/2026 at 08:00, 20 minutes ago VEON and Amdocs Enter 10-Year Strategic Agreement to Advance Digital Services powered by Amdocs' AI technology
Published on 10/07/2026 at 01:45, 6 hours 35 minutes ago Final Tunkillia Assays Among the Best Infill Results To-Date, with Broad, High-Grade Intersections Throughout 'Starter Pit' Outlines
Published on 10/07/2026 at 01:30, 6 hours 50 minutes ago ECC Ventures 4 Corp. Announces Resumption of Trading
Published on 10/07/2026 at 01:05, 7 hours 15 minutes ago Alaska Energy Metals Reports on At-The-Market Equity Financing Program
Published on 10/06/2026 at 23:45, 8 hours 35 minutes ago Gamma Resources Closes $1,750,000 Private Placement
Published on 10/07/2026 at 08:05, 15 minutes ago OncoBayes progressing OB-001 to tackle ADC resistance and TKI brain penetration
Published on 10/07/2026 at 08:05, 15 minutes ago Market Logic's DeepSights MCP scales market insights reach and business impact through enterprise-wide AI workflows
Published on 10/07/2026 at 08:00, 20 minutes ago New sports cars, greater exclusivity, stronger profitability: Porsche presents new strategy through to 2035
Published on 10/07/2026 at 07:30, 50 minutes ago Nordex Group records 389 MW of new orders in Türkiye
Published on 10/07/2026 at 08:15, 5 minutes ago EURAZEO TO ACQUIRE MIYA WATER, A GLOBAL SPECIALIST IN EFFICIENT WATER MANAGEMENT SOLUTIONS
Published on 10/07/2026 at 08:00, 20 minutes ago Neoen launches construction of its 346 MW Goyder North Wind Farm in South Australia
Published on 10/06/2026 at 19:15, 13 hours 5 minutes ago Air Liquide has successfully issued a 2 billion euros multi-tranche bond
Published on 10/06/2026 at 18:39, 13 hours 41 minutes ago Total number of voting rights and shares making up the share capital at September 30, 2026
Published on 10/06/2026 at 18:15, 14 hours 5 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 30/09/2026
